Compare Fortive Corporation Common Stock (FTV) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortive Corporation Common Stock vs Tango Therapeutics Inc. — how do they compare? Fortive Corporation Common Stock trades at $57.21 (market cap $17.54B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Fortive Corporation Common Stock is far larger — about 4.7× Tango Therapeutics Inc.'s market cap, and Fortive Corporation Common Stock pays a 0.48% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fortive Corporation Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| FTV | TNGX | |
|---|---|---|
Market Cap | $17.54B | $3.75B |
Volume | 1,898,662 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $64.09 | $32.90 |
52-Week Low | $48.49 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $20.67B | $2.77B |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortive Corporation (FTV) trades at $58.07, up 1.22% today, with a neutral technical signal and a consensus analyst price target of $63.33. The stock shows strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue growth is modest, but profitability remains solid with a 12.38% net income margin. Recent news highlights product launches and a dividend increase, while institutional activity includes mixed buying and selling.
The outlook is cautiously positive, supported by raised 2026 guidance and core growth acceleration. Key risks include competitive pressures and macroeconomic headwinds. Analyst sentiment is mixed, with 36.67% buy ratings, but the stock offers potential upside to the consensus target if execution continues to improve.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fortive Corporation Common Stock
Fortive provides industrial and healthcare technology solutions. Its products and software support measurement, maintenance, worker safety, instrument sterilization, and clinical workflows.
Read more on FTV →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
